Development and Early Feasibility of Chatbots for Educating Patients With Lung Cancer and Their Caregivers in Japan: Mixed Methods Study

Kataoka, Yuki; Takemura, Tomoyasu; Sasajima, Munehiko; Katoh, Naoki

doi:10.2196/26911

Cited by 22 publications

(27 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…AI development fostered fast market penetration of innovative messaging platforms and health chatbots. 36,37 Recently, a chatbot was designed to address identified disease knowledge gaps among PwH in Senegal. 38 This unique chatbot is designed to recognize voices speaking in French and Wolof (a common language in Senegal), providing text answers in both languages through a user-friendly interface integrated into both Android and Apple iOS devices.…”

Section: Artificial Intelligence In Haemophilia Carementioning

confidence: 99%

See 1 more Smart Citation

Therapeutic and technological advancements in haemophilia care: Quantum leaps forward

Lewandowska

Nasr²,

Shapiro

2022

Haemophilia

View full text Add to dashboard Cite

Introduction Recent technological innovations in haemophilia have advanced at an astounding pace, including gene therapy programmes and bioengineered molecules for prophylaxis, products that reduce treatment burden through half‐life extension, unique mechanisms of action, and subcutaneous administration. Additional technological advancements have emerged that are anticipated to further transform haemophilia care. Aim Review new and emerging haemophilia therapies, including replacement and bypassing products, digital applications, utilisation of big data, and personalised medicine. Methods Data were obtained from peer‐reviewed presentations/publications, and ongoing studies in haemophilia, ultrasonography, and artificial intelligence (AI). Results Available treatments include new recombinant factors VIII (FVIII) and IX (FIX), extended half‐life FVIII/IX products, a new FVIIa product for inhibitor patients, and a FVIIIa‐mimetic. Several novel therapeutics are in clinical trials, including FVIIIa mimetics and inhibitors of naturally‐occurring anticoagulants. Ongoing gene therapy trials suggest that a single vector infusion using an optimised construct can produce factor activity that reduces bleeding to near zero for years. Today, persons with haemophilia (PwH) approach a lifespan comparable to that of the general population, presenting treatment challenges for age‐related co‐morbidities. Technological innovations have broadened beyond therapeutics to include large database analyses utilising remote data collection with handheld devices, and to tailor AI applications. Current development efforts include patient‐performed ultrasonography, algorithms for scan interpretation, and point‐of‐care haemostatic testing devices. Conclusions We have entered a golden age for haemophilia treatment and care with wide‐ranging advancements targeting improved quality of life (QoL). Future‐focused efforts by clinical and patient communities may provide equitable access and care for people impacted by haemophilia worldwide.

show abstract

Section: Artificial Intelligence In Haemophilia Carementioning

confidence: 99%

“…AI development fostered fast market penetration of innovative messaging platforms and health chatbots 36,37 . Recently, a chatbot was designed to address identified disease knowledge gaps among PwH in Senegal 38 .…”

Section: Technological Advances In Carementioning

confidence: 99%

Therapeutic and technological advancements in haemophilia care: Quantum leaps forward

Lewandowska

Nasr²,

Shapiro

2022

Haemophilia

View full text Add to dashboard Cite

show abstract

“…Applications of ML models in clinical practice have been prominent in the field of diagnostic imaging, such as the diagnosing bone fractures, 1 detection of breast cancer, 2 and COVID‐19 diagnosis 3 . Clinical implementation is not limited to diagnosis but is expanding into alerts, 4 patient education, 5 and many other areas.…”

Section: Introductionmentioning

confidence: 99%

An open competition involving thousands of competitors failed to construct useful abstract classifiers for new diagnostic test accuracy systematic reviews

Kataoka

Taito

Yamamoto

et al. 2023

Research Synthesis Methods

Self Cite

View full text Add to dashboard Cite

There are currently no abstract classifiers, which can be used for new diagnostic test accuracy (DTA) systematic reviews to select primary DTA study abstracts from database searches. Our goal was to develop machine‐learning‐based abstract classifiers for new DTA systematic reviews through an open competition. We prepared a dataset of abstracts obtained through database searches from 11 reviews in different clinical areas. As the reference standard, we used the abstract lists that required manual full‐text review. We randomly splitted the datasets into a train set, a public test set, and a private test set. Competition participants used the training set to develop classifiers and validated their classifiers using the public test set. The classifiers were refined based on the performance of the public test set. They could submit as many times as they wanted during the competition. Finally, we used the private test set to rank the submitted classifiers. To reduce false exclusions, we used the Fbeta measure with a beta set to seven for evaluating classifiers. After the competition, we conducted the external validation using a dataset from a cardiology DTA review. We received 13,774 submissions from 1429 teams or persons over 4 months. The top‐honored classifier achieved a Fbeta score of 0.4036 and a recall of 0.2352 in the external validation. In conclusion, we were unable to develop an abstract classifier with sufficient recall for immediate application to new DTA systematic reviews. Further studies are needed to update and validate classifiers with datasets from other clinical areas.

show abstract

“…[4] Artificial intelligence (AI) can support respiratory care: for example interpreting chest X-rays and sleep studies, [6,7] predicting acute exacerbations of chronic obstructive lung disease (COPD), [8] and chatbots answering questions from people with lung cancer. [9] Effective implementation strategies, however, are poorly developed, [10] and the potential for AI to replace (as opposed to support) clinical decision-making [11] currently outstrips the trust of many patients and professionals. [12,13] Whilst we are mindful of this wider perspective, in this clinical review we focus on selected examples to provide an expert perspective on the potential of telemedicine to deliver virtual respiratory care.…”

Section: Introductionmentioning

confidence: 99%

Telemedicine and virtual respiratory care in the era of COVID-19

Pinnock

Murphie²,

Vogiatzis

et al. 2022

ERJ Open Res

View full text Add to dashboard Cite

The World Health Organization defines telemedicine as “an interaction between a health care provider and a patient when the two are separated by distance”. The COVID-19 pandemic has forced a dramatic shift to telephone and video consulting for follow up and routine ambulatory care for reasons of infection control. Short Message Service (“text”) messaging has proved a useful adjunct to remote consulting allowing transfer of photographs and documents. Maintaining non-communicable diseases care is a core component of pandemic preparedness and telemedicine has developed to enable (for example) remote monitoring of sleep apnoea, telemonitoring of chronic obstructive pulmonary disease, digital support for asthma self-management, remote delivery of pulmonary rehabilitation. There are multiple exemplars of telehealth instigated rapidly to provide care for people with COVID-19, to manage the spread of the pandemic, or to maintain safe routine diagnostic or treatment services.Despite many positive examples of equivalent functionality and safety, there remain questions about the impact of remote delivery of care on rapport and the longer-term impact on patient/professional relationships. Although telehealth has the potential to contribute to universal health coverage by providing cost-effective accessible care, there is a risk of increasing social health inequalities if the “digital divide” excludes those most in need of care. As we emerge from the pandemic, the balance of remote versus face-to-face consulting, and the specific role of digital health in different clinical and healthcare contexts will evolve. What is clear is that telemedicine in one form or another will be part of the “new norm”.

show abstract

Development and Early Feasibility of Chatbots for Educating Patients With Lung Cancer and Their Caregivers in Japan: Mixed Methods Study

Cited by 22 publications

References 13 publications

Therapeutic and technological advancements in haemophilia care: Quantum leaps forward

Therapeutic and technological advancements in haemophilia care: Quantum leaps forward

An open competition involving thousands of competitors failed to construct useful abstract classifiers for new diagnostic test accuracy systematic reviews

Telemedicine and virtual respiratory care in the era of COVID-19

Contact Info

Product

Resources

About